01—Abstract
Summary
Summary of the 8-K filed August 1, 2025. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. (MRNA) has filed an 8-K report on August 1, 2025, to announce its financial results for the second quarter ended June 30, 2025.
The primary driver of this filing is the accompanying press release, furnished as Exhibit 99.1, which details the company's performance during the quarter. Investors should note that this information is furnished and not deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, meaning it does not carry the same level of regulatory liability as a fully filed document, though it is still critical for understanding the company's operational and financial standing. While the 8-K itself is brief, the press release (Exhibit 99.1) is expected to contain key financial metrics such as revenue, earnings per share, and cash flow, along with qualitative commentary on business developments, pipeline progress, and future outlook.
Investors are encouraged to review the press release for specific details regarding sales of existing products, advancements in clinical trials for new therapies, and any strategic partnerships or collaborations. The filing also includes the cover page interactive data file in XBRL format for enhanced data analysis.
02—Key points
Key Highlights
- Moderna announced its second quarter 2025 financial results via press release on August 1, 2025.
- The 8-K filing incorporates by reference the press release containing the detailed financial and operational results.
- Key financial metrics for Q2 2025 are expected to be disclosed in the furnished press release.
- The filing is furnished and not deemed 'filed' under Section 18 of the Exchange Act, impacting specific regulatory liabilities.
- Investors should refer to the press release (Exhibit 99.1) for comprehensive performance details and business updates.
- The filing includes the Cover Page Interactive Data File in XBRL format.
03—Questions
Frequently Asked Questions
What is the main purpose of this 8-K filing?
The main purpose of this 8-K filing is to formally announce and provide access to Moderna, Inc.'s financial results for the second quarter ended June 30, 2025, through an accompanying press release.
Where can I find the detailed financial results?
The detailed financial results and operational commentary are contained within the press release issued by Moderna, Inc. on August 1, 2025, which is furnished as Exhibit 99.1 to this 8-K filing and incorporated by reference.
What is the significance of the information being 'furnished' versus 'filed'?
Information that is 'furnished' (as is the case with the press release in this filing) is generally not subject to the same liability provisions under Section 18 of the Securities Exchange Act of 1934 as information that is 'filed'. However, it still provides crucial updates for investors. The press release is not considered part of a registration statement unless explicitly incorporated by reference into one.
What other information is included in this filing?
In addition to the press release announcing the Q2 2025 financial results, the filing also includes the Cover Page Interactive Data File, which is embedded within the Inline XBRL document.
04—Continue